SHC: third-quarter revenue and adjusted EBITDA rise, European softness tempers Sterigenics
According to TradingView, SHC grew third-quarter revenue and adjusted EBITDA and reaffirmed 2026 guidance, but expects Sterigenics Q4 revenue to stay flat sequentially.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
SHC reported growth in third-quarter revenue and adjusted EBITDA. Margins improved sequentially, and its 2026 guidance was reaffirmed. Net leverage reached 2.9x, which points to progress on the balance sheet.
The company expects softness in European medical device demand to keep Sterigenics revenue flat from the third quarter to the fourth. The report was published by TradingView and is based on an AI-generated summary.
why it matters
For investors, the key question is whether the momentum lasts: a solid quarter supports SHC stock, but the flat Sterigenics outlook limits expectations for the near term. The news matters mainly for the company's shares and the medical technology sector.
market impact
SHC shares: solid quarter offset by flat Sterigenics outlook, pressure in both directions
- SHC shares mixed — strong reported growth supports the stock, while flat Sterigenics Q4 revenue weighs on it
tags
instruments
sources
- SHC: Q3 growth and balance-sheet progress; European softness tempers Sterigenics Q4 momentum — TradingView, 3 November 2026 at 17:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗